A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag
Status:
NOT_YET_RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
In a prospective, single-arm study, the efficacy and safety of Lusutrombopag in the treatment of relapsed/refractory/intolerable non-severe aplastic anemia (NSAA) were explored.